PD-1 blockage delays murine squamous cell carcinoma development

Area of Science:

• Immunology
• Oncology
• Dermatology

Background:

• Programmed death-1 (PD-1) engagement with its ligands (PD-L1, PD-L2) inhibits tumor-reactive T cells, but the mechanism remains unclear.
• PD-1/PD-L1 signaling is implicated in immune evasion by various cancers, including squamous cell carcinoma (SCC).

Purpose of the Study:

• To investigate the role of PD-1/PD-L1 signaling in the immune evasion mechanisms of SCC.
• To determine if PD-1/PD-L1 interactions contribute to SCC progression by modulating the tumor microenvironment.

Main Methods:

• Utilized a multistage mouse model of SCC.
• Analyzed T cell populations (CD4+, CD8+) and PD-1 expression in tumor sites.
• Assessed PD-L1 expression on macrophages (F4/80+).
• Administered systemic immune neutralization of PD-1 and evaluated tumor development and immune markers.

Main Results:

• Tumor sites showed increased PD-1 expression on CD4+ and CD8+ T cells compared to controls.
• PD-L1 expression was notably elevated on macrophages within tumor sites.
• Blocking PD-1 led to reduced papilloma incidence and delayed tumor development.
• PD-1 blockade increased CD8+, CD4+ T cell percentages and interferon-gamma levels at tumor sites.

Conclusions:

• PD-1(+) T cells are involved in SCC development.
• The PD-1/PD-L1 pathway contributes to SCC progression by downregulating anti-tumor immune responses.
• Modulating the PD-1/PD-L1 interaction can enhance anti-tumor immunity in SCC.